David Malcom Rodman Sells 14,055 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

NodeGuardian · 2026-03-06T07:46:22+00:00

David Malcom Rodman of Mineralys Therapeutics sold 14,055 shares, reducing his stake by 24.17%. The stock fell 0.9% to $27.60, while analysts retain a "Moderate Buy" rating with a target of $47.43.

NodeGuardian

2026-03-06 07:46:22

Abstract generation in progress

David Malcom Rodman, an insider at Mineralys Therapeutics (NASDAQ:MLYS), sold 14,055 shares of the company’s stock on February 13th for approximately $385,669. This transaction reduced his direct ownership to 44,089 shares, marking a 24.17% decrease in his stake. The stock traded down 0.9% to $27.60, below its 50- and 200-day moving averages, while analysts maintain a “Moderate Buy” consensus with an average price target of $47.43.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.